慢性荨麻疹与单克隆IgM丙种球蛋白病（施尼茨勒综合征）：11例培氟沙星治疗报告
Chronic urticaria and monoclonal IgM gammopathy (Schnitzler syndrome): report of 11 cases treated with pefloxacin.
作者信息
Asli Bouchra, Bienvenu Boris, Cordoliani Florence, Brouet Jean-Claude, Uzunhan Yurdagul, Arnulf Bertrand, Malphettes Marion, Rybojad Michel, Fermand Jean-Paul
机构信息
Service d'Immunohématologie, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France.
出版信息
Arch Dermatol. 2007 Aug;143(8):1046-50. doi: 10.1001/archderm.143.8.1046.
BACKGROUND
Schnitzler syndrome is characterized by chronic urticarial rash and monoclonal IgM gammopathy and is sometimes associated with periodic fever, arthralgias, and bone pain. Current treatment is unsatisfactory.
OBSERVATIONS
Eleven patients with Schnitzler syndrome were treated with oral pefloxacin mesylate (800 mg/d). In 10 patients, we observed a dramatic and sustained improvement of urticarial and systemic manifestations. Corticosteroid therapy could be stopped or reduced in 6 patients. In 9 patients, pefloxacin was administered for more than 6 months (<or= 10 years), with a good safety profile.
CONCLUSIONS
Pefloxacin therapy can be considered for patients with Schnitzler syndrome because it usually improves chronic urticaria and the systemic symptoms of the disease.
背景
施尼茨勒综合征的特征为慢性荨麻疹皮疹和单克隆IgM丙种球蛋白病，有时还伴有周期性发热、关节痛和骨痛。目前的治疗效果并不理想。
观察结果
11例施尼茨勒综合征患者接受口服甲磺酸培氟沙星治疗（800毫克/天）。在10例患者中，我们观察到荨麻疹和全身症状有显著且持续的改善。6例患者可以停用或减少皮质类固醇治疗。9例患者接受培氟沙星治疗超过6个月（≤10年），安全性良好。
结论
施尼茨勒综合征患者可考虑使用培氟沙星治疗，因为它通常能改善慢性荨麻疹及该病的全身症状。
Zotero 插件